• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series.

作者信息

Ten Hagen Alexander, Habermann Elisa, Hermann Sandra, Burmester Gerd R, Biesen Robert, Albach Fredrik N

机构信息

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität, Berlin, Germany.

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität, Berlin, Germany

出版信息

RMD Open. 2022 Dec;8(2). doi: 10.1136/rmdopen-2022-002567.

DOI:10.1136/rmdopen-2022-002567
PMID:36597976
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9729842/
Abstract
摘要

相似文献

1
Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series.在接受利妥昔单抗诱导的B细胞耗竭的风湿性疾病患者中，尽管反复接种疫苗后抗体反应不足，但仍出现轻度新型冠状病毒肺炎：病例系列
RMD Open. 2022 Dec;8(2). doi: 10.1136/rmdopen-2022-002567.
2
Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).在接受利妥昔单抗治疗的炎症性风湿病患者中 COVID-19 疫苗的体液免疫原性：一项病例对照研究（COVID-19VacRTX）。
Rheumatology (Oxford). 2022 Oct 6;61(10):3912-3918. doi: 10.1093/rheumatology/keac036.
3
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.疫苗类型和免疫抑制治疗，但不是诊断，对风湿性疾病患者 COVID-19 疫苗接种后的抗体反应有重要影响。
RMD Open. 2022 Dec;8(2). doi: 10.1136/rmdopen-2022-002650.
4
Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination.在患有自身免疫性风湿病的 B 细胞耗竭患者中，流感疫苗接种后可有效增强抗病毒 T 细胞反应。
Clin Exp Rheumatol. 2013 Sep-Oct;31(5):723-30. Epub 2013 Jun 14.
5
A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.接种疫苗（包括 COVID-19 疫苗）在自身免疫/炎症性风湿病中的实用方法：非系统性综述。
Clin Rheumatol. 2021 Sep;40(9):3533-3545. doi: 10.1007/s10067-021-05700-z. Epub 2021 Mar 22.
6
B Cell Reconstitution Is Strongly Associated With COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Who Received Treatment With Rituximab.B 细胞重建与 COVID-19 疫苗应答密切相关，在接受利妥昔单抗治疗的风湿性疾病患者中亦是如此。
Arthritis Rheumatol. 2022 May;74(5):776-782. doi: 10.1002/art.42034. Epub 2022 Mar 15.
7
Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.利妥昔单抗治疗后时间对于风湿性疾病患者对 COVID-19 mRNA 疫苗产生体液免疫反应至关重要。
J Rheumatol. 2022 Jun;49(6):644-649. doi: 10.3899/jrheum.211152. Epub 2022 Mar 1.
8
Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.风湿与肌肉骨骼疾病患者感染 SARS-CoV-2 及接种 SARS-CoV-2 疫苗的风险和预后：一项系统文献综述，旨在为 EULAR 建议提供信息。
Ann Rheum Dis. 2022 Mar;81(3):422-432. doi: 10.1136/annrheumdis-2021-221575. Epub 2021 Dec 7.
9
Response to: 'Correspondence on 'SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease'' by C .对C.所著《关于“风湿性疾病患者感染COVID-19后针对SARS-CoV-2的抗体反应”的通信》的回应
Ann Rheum Dis. 2023 Jun;82(6):e131. doi: 10.1136/annrheumdis-2021-220166. Epub 2021 Mar 10.
10
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.

引用本文的文献

1
Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.免疫调节治疗对免疫介导性疾病和原发性免疫缺陷患者 COVID-19 加强疫苗接种前后 B 细胞相关和 T 细胞相关免疫反应的影响：一项队列研究。
RMD Open. 2023 Aug;9(3). doi: 10.1136/rmdopen-2023-003094.
2
Bivalent vaccination against COVID-19 can trigger a humoral response in immunocompromised patients who receive monoclonal antibody prophylaxis.针对新冠病毒的二价疫苗接种可在接受单克隆抗体预防的免疫功能低下患者中引发体液免疫反应。
J Nephrol. 2023 Jul;36(6):1719-1721. doi: 10.1007/s40620-023-01699-5. Epub 2023 Jul 6.

本文引用的文献

1
Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis.B 细胞耗竭治疗的免疫介导性疾病患者突破性 SARS-CoV-2 感染：一项回顾性队列分析。
Arthritis Rheumatol. 2022 Dec;74(12):1906-1915. doi: 10.1002/art.42287. Epub 2022 Oct 31.
2
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses.在用利妥昔单抗治疗的自身免疫性疾病患者及对两剂新冠疫苗无反应者中，接种第三剂新冠疫苗后体液免疫反应率极低。
RMD Open. 2022 May;8(1). doi: 10.1136/rmdopen-2022-002308.
3
Estimating disease severity of Omicron and Delta SARS-CoV-2 infections.估算奥密克戎和德尔塔 SARS-CoV-2 感染的疾病严重程度。
Nat Rev Immunol. 2022 May;22(5):267-269. doi: 10.1038/s41577-022-00720-5.
4
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant.祖先 SARS-CoV-2 特异性 T 细胞交叉识别奥密克戎变体。
Nat Med. 2022 Mar;28(3):472-476. doi: 10.1038/s41591-022-01700-x. Epub 2022 Jan 14.
5
Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.利妥昔单抗可抑制自身免疫性疾病患者对 COVID-19 疫苗的 B 细胞应答，但不影响 T 细胞应答。
Arthritis Rheumatol. 2022 Jun;74(6):927-933. doi: 10.1002/art.42058. Epub 2022 Mar 29.
6
A minimal common outcome measure set for COVID-19 clinical research.用于 COVID-19 临床研究的最小通用结局指标集。
Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12.